KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Leases (2019 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Current Leases for 7 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 13.43% to $36.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.1 million through Dec 2025, down 13.43% year-over-year, with the annual reading at $36.1 million for FY2025, 13.43% down from the prior year.
  • Current Leases for Q4 2025 was $36.1 million at Bio-Rad Laboratories, down from $36.8 million in the prior quarter.
  • The five-year high for Current Leases was $42.8 million in Q3 2024, with the low at $34.0 million in Q3 2022.
  • Average Current Leases over 5 years is $38.1 million, with a median of $36.8 million recorded in 2022.
  • The sharpest move saw Current Leases increased 14.85% in 2023, then fell 14.09% in 2025.
  • Over 5 years, Current Leases stood at $36.4 million in 2021, then decreased by 0.27% to $36.3 million in 2022, then increased by 11.18% to $40.4 million in 2023, then increased by 3.22% to $41.7 million in 2024, then dropped by 13.43% to $36.1 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $36.1 million, $36.8 million, and $39.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.